GB1042194A - Insulin preparations - Google Patents
Insulin preparationsInfo
- Publication number
- GB1042194A GB1042194A GB14107/63A GB1410763A GB1042194A GB 1042194 A GB1042194 A GB 1042194A GB 14107/63 A GB14107/63 A GB 14107/63A GB 1410763 A GB1410763 A GB 1410763A GB 1042194 A GB1042194 A GB 1042194A
- Authority
- GB
- United Kingdom
- Prior art keywords
- insulin
- desalanino
- desalamino
- protamine
- alkaline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 26
- 102000004877 Insulin Human genes 0.000 title abstract 13
- 108090001061 Insulin Proteins 0.000 title abstract 13
- 229940125396 insulin Drugs 0.000 title abstract 13
- 238000002360 preparation method Methods 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 102000007327 Protamines Human genes 0.000 abstract 2
- 108010007568 Protamines Proteins 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 2
- 229940048914 protamine Drugs 0.000 abstract 2
- 239000011701 zinc Substances 0.000 abstract 2
- 229910052725 zinc Inorganic materials 0.000 abstract 2
- 241000251468 Actinopterygii Species 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000283153 Cetacea Species 0.000 abstract 1
- 108010033040 Histones Proteins 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 102000018146 globin Human genes 0.000 abstract 1
- 108060003196 globin Proteins 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000008223 sterile water Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Desalanino insulin (i.e. insulin in which the C-terminal alanine groups have been removed) is prepared by treating an aqueous solution of insulin having an alkaline pH e.g. pH 7.8 with an aqueous solution of carboxypetidase having an alkaline pH e.g. pH 8.0, incubating 5 hours at 37 DEG C, and adjusting to pH 5.4 with hydrochloric acid to precipitate the desalamino insulin. The insulin may be derived from the pancreas of pigs, cattle, whales and fish. For injection, the insulin is dissolved in sterile water at pH 2 to 4, preferably buffered, and also containing sodium chloride and/or glycerin and a preservative such as phenol or m-cresol. The desalanino insulin may be used per se, as zinc desalanino insulin, protamine desalanino insulin, histone desalamino insulin, globin desalanino insulin or protamine &c. zinc desalanino insulin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19129362A | 1962-04-30 | 1962-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1042194A true GB1042194A (en) | 1966-09-14 |
Family
ID=22704899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB14107/63A Expired GB1042194A (en) | 1962-04-30 | 1963-04-09 | Insulin preparations |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2800M (en) |
| GB (1) | GB1042194A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011141407A1 (en) * | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| US8828923B2 (en) | 2003-08-05 | 2014-09-09 | Novo Nordisk A/S | Insulin derivatives |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US10596229B2 (en) | 2010-10-27 | 2020-03-24 | Novo Nordisk A/S | Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action |
| US11167035B2 (en) | 2005-12-28 | 2021-11-09 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
-
1963
- 1963-04-09 GB GB14107/63A patent/GB1042194A/en not_active Expired
- 1963-04-25 FR FR932599A patent/FR2800M/en not_active Expired
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8828923B2 (en) | 2003-08-05 | 2014-09-09 | Novo Nordisk A/S | Insulin derivatives |
| US11167035B2 (en) | 2005-12-28 | 2021-11-09 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| WO2011141407A1 (en) * | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| AU2011252127B2 (en) * | 2010-05-10 | 2014-02-20 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| CN107029212A (en) * | 2010-05-10 | 2017-08-11 | 诺沃—诺迪斯克有限公司 | Method for preparing zinc insulin compound |
| US10596229B2 (en) | 2010-10-27 | 2020-03-24 | Novo Nordisk A/S | Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12226458B2 (en) | 2018-06-26 | 2025-02-18 | Novo Nordisk A/S | System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2800M (en) | 1964-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69021335D1 (en) | GROWTH HORMON FUSION PROTEINS. | |
| SE8101065L (en) | ANTITROMBINBEREDNING | |
| GB1042194A (en) | Insulin preparations | |
| Valenta et al. | Polymorphism of transferrin in carp (Cyprinus carpio L.): genetic determination, isolation, and partial characterization | |
| Matty et al. | The production of exophthalmos by androgens in two species of teleost fish | |
| GB1110466A (en) | Process for the production of lysozyme | |
| Moloney et al. | NEUTRALIZATION OF COD INSULIN WITH ANTISERUM: PRECIPITATION OF INSULIN–ANTI-INSULIN COMPLEX WITH ETHANOL–WATER | |
| Beadle et al. | Carbon dioxide narcosis | |
| Greenbaum et al. | The effect of pituitary growth hormone and of insulin on the level of oxidized and reduced coenzyme I in the livers of normal and diabetic rats | |
| Leone | Ergothioneine in the equine ampullar secretion | |
| ES359547A1 (en) | Lupus erythematosus skin test | |
| Hess et al. | The Colorimetric Determination of Cystine in Tobacco Mosaic Virus Protein | |
| Jørgensen et al. | Relative effectiveness of dehydration and neurohypophysial extracts in enhancing water absorption in toads and frogs | |
| GB1188347A (en) | Preservation of Semen | |
| Yamaguchi et al. | Effects of thyroxine and prolactin on the rates of protein synthesis in the thigh bones of the tadpole of Rana catesbeiana | |
| Kawai et al. | Paralytic and digestive activities of jelly-like substances secreted by a lysaretid polychaete, Halla okudai | |
| Cutts et al. | Nutrition of a strain of brewer's yeast requiring p-aminobenzoic acid | |
| Pincus | Qualitative tests on human enamel protein | |
| GB918754A (en) | Improvements in or relating to corticotrophin preparations | |
| FI60576B (en) | FOERFARANDE FOER FRAMSTAELLNING AV LYSOZYM | |
| SAKUMA | The fate of the glyoxals in the animal body | |
| Swingle | Iodine and anuran metamorphosis | |
| GB1027036A (en) | Despeciated interferon | |
| Sato | Control of botulism in poultry flocks. | |
| SE8300808L (en) | PROCEDURE FOR THE CONSERVATION OF STRONG WATER-SUBSTANTIAL ANIMAL FEED, SPECIAL FISH NILAGE, FOR USE IN FUR ANIMAL FEED AND CONSERVATOR FOR USE IN THE PROCEDURE |